Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0000-0001-6287-7391
Kelli O'ConnellDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Jenna BhimaniDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-9962-7019
Grace B GallagherDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0009-0004-9277-5002
Victoria S BlinderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-1448-8671
Rachael Burganowski DoudKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0009-0004-2179-9816
Isaac J ErgasDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0002-3187-9754
Jennifer J GriggsDivision of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, United States.
Narre HeonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0009-0003-5239-0821
Tatjana KolevskaDepartment of Oncology, Kaiser Permanente Medical Center, Vallejo, CA, United States.ORCID 0009-0003-5704-539X
Yuriy KotsurovskyyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-1288-518X
Candyce H KroenkeDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0002-6128-3118
Cecile A LaurentDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0001-9332-6971
Raymond LiuDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0002-4667-9632
Kanichi G NakataKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0000-0001-6730-6045
Sonia PersaudDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0009-0008-5666-7994
Donna R RiveraOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, United States.ORCID 0000-0002-4565-4556
Janise M RohDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.
Sara TabatabaiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-5498-7176
Emily ValiceDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0003-2408-9727
Peng WangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0003-4303-6081
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, United States.ORCID 0000-0002-8789-2755
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.ORCID 0000-0001-9136-1175
Elizabeth D KantorDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0002-9124-5323
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Infrastructure for Pathways, a Prospective Study of Breast Cancer SurvivorshipU01CA195565 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI AMBROSONE, CHRISTINE B., KUSHI, LAWRENCE H · 2016 to 2025
$18.8M
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care SystemsU24CA171524 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2012 to 2016
$16.0M
Obesity, chemotherapy dosing, and breast cancer outcomesR37CA222793 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KANTOR, ELIZABETH DAVID · 2018 to 2024
$4.0M
Predictors of CVD among breast cancer survivors in an integrated health systemR01CA214057 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI GREENLEE, HEATHER, KWAN, MARILYN L · 2017 to 2020
$2.6M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
Geoffrey Beene Cancer Research Center at Memorial Sloan Kettering Cancer CenterNCI NIH HHS P01 CA154292NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA214057NCI NIH HHS R37 CA222793NCI NIH HHS R50 CA211115NCI NIH HHS U01 CA195565NCI NIH HHS U24 CA171524NIH HHS P01CA154292NIH HHS P30CA008748NIH HHS R01CA214057NIH HHS R37CA222793NIH HHS R50CA211115NIH HHS U01CA195565NIH HHS U24CA171524
6 · The paper itself
Abstract
backgroundOlder women (>65 years) diagnosed with breast cancer may be at risk for chemotherapy dose reductions. We evaluated associations of age at diagnosis with 2 measures of chemotherapy dose reductions: first cycle dose proportion (FCDP) < 90% and average relative dose intensity (ARDI) < 90%.
methodsFrom the Optimal Breast Cancer Chemotherapy Dosing study, we included 10 166 women aged 18+ years treated with adjuvant chemotherapy for stage I-IIIA breast cancer at Kaiser Permanente Northern California (KPNC) and Washington (KPWA) between 2004 and 2019. We examined associations between age at diagnosis with FCDP < 90% (reflecting clinician intent at chemotherapy initiation) and ARDI < 90% (reflecting average dose across the chemotherapy course). We used generalized linear models of the Poisson family with a log-link function and robust standard errors to calculate prevalence ratios (PR) for FCDP < 90% and ARDI < 90% with 95% confidence intervals (CI) adjusted for patient and tumor characteristics, with and without adjusting for pre-existing comorbidities. All tests for statistical significance were 2-sided.
resultsThe proportion of women with FCDP < 90% ranged from 2.9% among women aged 18-39 years to 18.6% among women aged 75+ years. Before adjusting for comorbidities, women aged 75+ years were more likely to have FCDP < 90% (PR = 4.88; 95% CI = 3.58 to 6.66) and ARDI < 90% (PR = 1.91; 95% CI = 1.58 to 2.32) versus women aged 40-49 years. Results were similar after adjusting for comorbidities as a composite comorbidity score or individual comorbidities.
conclusionOlder age at diagnosis was strongly associated with chemotherapy dose reductions in this population-based cohort, particularly at chemotherapy initiation but also across the course of treatment.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer. · full record | OpenQuestion